Company profile: Dyne Therapeutics
1.1 - Company Overview
Company description
- Provider of targeted therapies for serious muscle diseases, including DYNE-101 for myotonic dystrophy type 1 to reduce mutant DMPK RNA, DYNE-251 for Duchenne muscular dystrophy amenable to exon 51 skipping to enable truncated, functional dystrophin, and DYNE-301 for facioscapulohumeral muscular dystrophy by reducing DUX4 expression; uses its FORCE platform to develop targeted oligonucleotide therapeutics and conducts clinical trials.
Products and services
- FORCE Platform: A proprietary system that architects targeted oligonucleotide therapeutics for muscle diseases, engineered to overcome limitations in delivery to muscle tissue
- DYNE-251: A therapeutic candidate for DMD amenable to exon 51 skipping, custom-engineered to enable production of a truncated, functional dystrophin protein
- DYNE-101: An investigational DM1 therapy, nucleus-targeted to reduce levels of mutant DMPK RNA in the nucleus
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Dyne Therapeutics
Bavarian Nordic
HQ: Denmark
Website
- Description: Provider of novel vaccines for the treatment and prevention of life-threatening diseases with large unmet medical need, focused on biodefence, cancer and infectious diseases. Product portfolio includes MVA-BN, a non-replicating vaccine for immunization against smallpox and mpox, approved in various countries and supplied to national stockpiles.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bavarian Nordic company profile →
Alaunos Therapeutics
HQ: United States
Website
- Description: Provider of TCR-T cell therapies and supporting platforms for cancer treatment, including non-viral TCR-T therapy for solid tumors, the Sleeping Beauty transposition system for TCR gene transfer, the hunTR discovery engine to identify new TCRs, and a clinical TCR library targeting frequent mutations such as KRAS, TP53, and EGFR, backed by in-house manufacturing for rapid, cost-effective TCR-T production.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alaunos Therapeutics company profile →
Vyriad
HQ: United States
Website
- Description: Provider of clinical-stage oncolytic virotherapies and gene therapy platforms, including Voyager-V1 (VSV-based oncolytic virotherapy in trials for multiple cancers), Measles-NIS (oncolytic measles virus encoding NIS for precision targeting and monitoring), oncolytic virus platforms using VSV and measles, in vivo gene therapy vectors, and engineered lentiviral vectors; conducts phase 1/2 clinical trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vyriad company profile →
Vivace Therapeutics
HQ: United States
Website
- Description: Provider of small-molecule YAP-TEAD transcription activity inhibitors targeting the Hippo-YAP pathway for cancer treatment, with a focus on Hippo-YAP pathway research to discover and develop cancer therapeutics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vivace Therapeutics company profile →
Turnstone Biologics
HQ: United States
Website
- Description: Provider of clinical-stage cancer immunotherapies leveraging two complementary platforms: Selected TIL therapies and viral immunotherapy for solid tumors. Offerings include TIDAL-01 and TIDAL-02 Selected TILs, RIVAL-01 viral immunotherapy, and combination Selected TILs + Virus approaches to enhance TIL trafficking and infiltration.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Turnstone Biologics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Dyne Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Dyne Therapeutics
2.2 - Growth funds investing in similar companies to Dyne Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Dyne Therapeutics
4.2 - Public trading comparable groups for Dyne Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →